Literature DB >> 7523147

Segregation of APO-1/Fas antigen- and tumor necrosis factor receptor-mediated apoptosis.

M Grell1, P H Krammer, P Scheurich.   

Abstract

The cytokine tumor necrosis factor (TNF) and the APO-1/Fas ligand represent typical inducers of apoptosis, i.e. programmed cell death. A limited sequence homology between the TNF receptor TR60 (p55) and the APO-1/Fas (CD95) antigen in their intracellular domains suggests overlapping signaling pathways. The TNF-sensitive cell line KYM-1, which expresses high numbers of both TNF receptors and the APO-1/Fas antigen, is highly sensitive towards triggering of apoptosis by each of the TNF receptors, but resistant to APO-1/Fas stimulation. The opposite response pattern was obtained using the B lymphoid line SKW 6.4, which also co-expresses all three cell surface molecules. Furthermore, no co-modulation of APO-1/Fas by down-regulation of cell surface expressed TR60 and/or TR80 receptors, and vice versa, was found. These data argue against a physical interaction of TNF receptors with APO-1/Fas and, in addition, demonstrate cell specific control of induction of apoptosis and usage of distinct signaling pathways by these receptor molecules.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523147     DOI: 10.1002/eji.1830241045

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  Apoptosis in Endocrine Glands.

Authors:  George Kontogeorgos; Kalman Kovacs
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

2.  The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure.

Authors:  M Leist; F Gantner; G Künstle; I Bohlinger; G Tiegs; H Bluethmann; A Wendel
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

3.  CD95 expression in aged mice infected with tuberculosis.

Authors:  A D Roberts; I M Orme
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

Review 4.  Cell death and the immune response: a lesson from the privileged.

Authors:  T A Ferguson; T S Griffith
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

5.  Unmodified calcium concentrations in tumour necrosis factor receptor subtype-mediated apoptotic cell death.

Authors:  S M McFarlane; H M Anderson; S J Tucker; O J Jupp; D J MacEwan
Journal:  Mol Cell Biochem       Date:  2000-08       Impact factor: 3.396

6.  Tumor necrosis factor receptor p55 is essential for intrahepatic granuloma formation and hepatocellular apoptosis in a murine model of bacterium-induced fulminant hepatitis.

Authors:  H Tsuji; A Harada; N Mukaida; Y Nakanuma; H Bluethmann; S Kaneko; K Yamakawa; S I Nakamura; K I Kobayashi; K Matsushima
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

7.  Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis.

Authors:  Bree B Aldridge; Suzanne Gaudet; Douglas A Lauffenburger; Peter K Sorger
Journal:  Mol Syst Biol       Date:  2011-11-22       Impact factor: 11.429

8.  Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation.

Authors:  D Bryder; V Ramsfjell; I Dybedal; K Theilgaard-Mönch; C M Högerkorp; J Adolfsson; O J Borge; S E Jacobsen
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

9.  A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other.

Authors:  E E Varfolomeev; M P Boldin; T M Goncharov; D Wallach
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

10.  Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.

Authors:  J L Browning; K Miatkowski; I Sizing; D Griffiths; M Zafari; C D Benjamin; W Meier; F Mackay
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.